Trial Profile
Comparative Efficacy and Safety of Combined Radiotherapy and Adjuvant Hormone Therapy (Leuprorelin SR 11.25 mg) and Hormone Therapy Alone (Leuprorelin SR 11.25 mg) in Locally Advanced Prostate Cancer (T3-T4 or pT3 on Biopsy, N0, M0)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Leuprorelin (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- Sponsors Laboratoires Takeda
- 05 Jun 2018 Results assessing long-term oncological outcomes, presented at the 54th Annual Meeting of the American Society of Clinical Oncology
- 01 Aug 2012 Results published in European Urology.
- 06 Jun 2010 Results presented at ASCO 2010.